AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.
MacroGenics, Inc. is a biopharmaceutical company based in Rockville, Maryland, that specializes in the discovery and development of antibody-based therapeutics for cancer treatment. The company's pipeline includes several immuno-oncology candidates, such as Margetuximab, a monoclonal antibody currently in Phase III trials targeting HER2-expressing tumors, and Flotetuzumab, a DART molecule aimed at treating acute myeloid leukemia. Other investigational products include various monoclonal antibodies targeting immune checkpoints like PD-1 and B7-H3, as well as combination therapies that leverage multiple targets. MacroGenics employs advanced Fc engineering technology to enhance antibody functionality and is also exploring applications for autoimmune disorders and infectious diseases. The company has established strategic collaborations with several partners to advance its research and development efforts. Founded in 2000, MacroGenics is committed to innovating immunotherapeutics to address significant medical needs.
Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Abyrx, Inc. is a company that develops, manufactures, and distributes therapeutic devices specifically designed for surgical procedures. Founded in 2013 and based in Irvington, New York, Abyrx offers a range of products, including resorbable hemostatic bone putties and applicator devices. These innovative solutions are aimed at addressing bone bleeding and facilitating bone healing by adhering to bleeding surfaces. The company’s technology also enables the delivery of drugs directly to the bone, enhancing recovery processes in various surgical fields, including orthopedic, cranial, maxillofacial, trauma, cardiothoracic, and spine surgeries. Abyrx has expanded its portfolio through acquisitions, including the HEMASORB Resorbable Hemostatic Bone Putty and the rights to develop advanced polymer technology for bone applications.
Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Replicate Dental Technologies is dedicated to developing a solution in changing single tooth replacement with a patented, patient-friendly product that does not require drilling or destroying healthy teeth. It offers a minimally-invasive, patented medical device for replacing teeth. The company was founded in 2009 and is headquartered in Dublin, Ireland.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Sonetik AG is a Swiss company based in Bern that specializes in developing and manufacturing digital hearing aids designed for individuals with hearing impairments. The company offers a range of preset hearing aids, including models tailored for various common patterns of hearing loss, such as slightly sloping, steeply sloping, high frequency, and flat losses. By utilizing a specialized software system, Sonetik can efficiently match customers' hearing profiles with the appropriate hearing aid model, ensuring effective solutions without the need for extensive adjustments typically required by audiologists. This approach allows Sonetik to provide high-quality hearing aids at a significantly lower cost, making them an accessible option for many users. As a subsidiary of Harvard International plc, Sonetik operates on both national and international levels, aiming to enhance the auditory experience for a diverse clientele.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Private Equity Round in 2013
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Private Equity Round in 2011
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Aleva Neurotherapeutics SA, founded in 2008 and based in Lausanne, Switzerland, specializes in the development of advanced implantable deep brain stimulation (DBS) systems. The company's product lineup includes directSTIM, an intelligent directional electrode designed to enhance the precision of electrical stimulation, and spiderSTIM, a diagnostic system that maps three-dimensional areas in brain targets to improve surgical outcomes. Additionally, Aleva is working on cortiSTIM, a device for cortical stimulation. Utilizing microelectromechanical systems (MEMS) technology, Aleva's devices aim to optimize existing therapies and enable the targeting of new brain areas, facilitating faster and more accurate surgical placements. The company focuses on treating neurological conditions such as Parkinson's disease and essential tremors. Aleva has successfully completed acute clinical trials for its products and is ISO13485 certified, reflecting its commitment to quality standards in medical device manufacturing. To date, Aleva has raised significant funding from various investors to support its ongoing development efforts.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, specializing in the development of diagnostic instruments and disposable cartridge systems for decentralized laboratory and point-of-care environments. The company's flagship products include the io System, which detects infectious diseases such as chlamydia and MRSA, and Callisto, designed to accommodate various testing throughput requirements. Binx Health focuses on providing solutions for sexually transmitted infections and hospital-acquired infections. The company aims to enhance healthcare accessibility by delivering on-demand testing directly to consumers, utilizing its proprietary, desktop, PCR-based platforms and mobile offerings. Established in 2005, Binx Health has formed a strategic partnership with Sherlock Biosciences to further advance its innovative healthcare solutions.
Vaximm specializes in developing active immunotherapies, specifically oral T-cell vaccines, for cancer patients. The company's lead product candidate, VXM01, aims to target the tumor vasculature, a critical component for tumor growth beyond microscopic size. Vaximm's innovative approach utilizes modified attenuated bacteria as first-in-class oral T-cell activators, allowing for flexible targeting of various cancer-related antigens. Preclinical studies have demonstrated significant anti-tumor activity, and Vaximm is poised to advance into human clinical trials, marking a significant step in offering advanced treatment options for cancer patients.
Tioga Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of pruritus. It offers Asimadoline, an orally active kappa opioid receptor agonist used for the treatment of pruritus or itching associated with atopic dermatitis. The company was incorporated in 2005 and is based in San Diego, California.
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.
Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.
Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
ORTHOCON is a medical therapeutics company developing innovative absorbable products for orthopaedic and spine surgeries.
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Lumavita AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development and commercialization of innovative anti-infectives aimed at women's health. Founded in 2008, the company offers products such as FemiFect, an antibiotic designed to treat infections associated with vaginitis caused by bacteria, fungi, and protozoa, and SPK-601, which targets human papillomavirus (HPV) and herpes simplex virus (HSV). Lumavita markets its products through various distributors, positioning itself within the expanding biopharmaceutical sector in Switzerland. The company was previously known as Shogoo Pharmaceuticals, AG before rebranding in December 2007 and operates as a subsidiary of Shogoo Pharmaceuticals KK.
BioVascular is a clinical stage privately held biotechnology company developing “first in class†products for platelet mediated cardiovascular diseases. BioVascular’s initial product, saratin, is a polypeptide produced by recombinant means in yeast. This product was discovered by and licensed from Merck KGaA. BioVascular is conducting human clinical trials of saratin for use in hemodialysis access graft and peripheral artery grafts to reduce intimal hyperplasia, which can lead to failure of the graft.
Alpex Pharma SA is a pharmaceutical company based in Mezzovico-Vira, Switzerland, specializing in the research, development, and production of orally dispersible tablets (ODTs) and effervescent tablets. Established in 1983 and formerly known as Aesculapius Pharma SA, the company has gained recognition for its proprietary ODT technology, which enhances the delivery and efficacy of medications. Alpex Pharma operates advanced manufacturing and research facilities covering approximately 7,000 square meters, compliant with Good Manufacturing Practices (GMP) for both pharmaceutical and nutritional products. In addition to its product offerings, the company provides a range of development services, including drug-excipient compatibility studies, analytical method development, and stability studies, positioning itself as a significant player in the fast melt and effervescent tablet markets.
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.
Pevion Biotech is a biotechnology company that uses its proprietary technology platforms.
TargeGen, Inc. is a biopharmaceutical company that specializes in vascular biology, focusing on the discovery and development of small molecule kinase inhibitors. These inhibitors are designed to address issues such as vascular leakage, proliferation, and inflammation, which are associated with various serious medical conditions including heart attacks, cancer, and eye diseases. TargeGen's products aim to treat conditions like macular degeneration, diabetic macular edema, and diabetic retinopathy, as well as other ailments involving edema and unwanted blood vessel growth. Founded in 2002 and based in San Diego, California, the company was acquired by Sanofi Aventis in 2010.
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health.
The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life.
Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging.
Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
ORTHOCON is a medical therapeutics company developing innovative absorbable products for orthopaedic and spine surgeries.
Tioga Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for the treatment of pruritus. It offers Asimadoline, an orally active kappa opioid receptor agonist used for the treatment of pruritus or itching associated with atopic dermatitis. The company was incorporated in 2005 and is based in San Diego, California.
Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on discovering, developing and commercializing anti-infective products. It has two late-stage anti-infective product candidates, fidaxomicin and Pruvel (prulifloxacin). Optimer's development efforts are focused on products that treat gastrointestinal infections, and related diseases where therapies have limitations. Its product portfolio includes Fidaxomicin, Pruvel, CEM-101, OPT-822/OPT-821 Combination Therapy and OPT-88.
TargeGen, Inc. is a biopharmaceutical company that specializes in vascular biology, focusing on the discovery and development of small molecule kinase inhibitors. These inhibitors are designed to address issues such as vascular leakage, proliferation, and inflammation, which are associated with various serious medical conditions including heart attacks, cancer, and eye diseases. TargeGen's products aim to treat conditions like macular degeneration, diabetic macular edema, and diabetic retinopathy, as well as other ailments involving edema and unwanted blood vessel growth. Founded in 2002 and based in San Diego, California, the company was acquired by Sanofi Aventis in 2010.
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health. While we remain dedicated to this founding principle, Auxilium’s mission has expanded to include the development and marketing of novel treatment options for many of society’s unmet medical needs.
Eyetech Pharmaceuticals is a biopharmaceutical company that specializes in novel therapeutics to treat diseases of the eye. The company conducted research and development into wet age-related macular degeneration diseases, which was seen as a breakthrough in the field.
Valeant Pharmaceuticals International acquired Eyetech for US$22 million in 2012.